# Mezigdomide PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mezigdomide

> The PDUFA target action date for mezigdomide, sponsored by BRISTOL MYERS SQUIBB CO (BMY), is May 13, 2027, for relapsed or refractory multiple myeloma. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the mezigdomide PDUFA date?

The PDUFA target action date for mezigdomide, sponsored by BRISTOL MYERS SQUIBB CO (BMY), is May 13, 2027, for relapsed or refractory multiple myeloma. Status: scheduled. Press release filed with the SEC (EX-99): "The FDA accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM), granting a PDUFA date of May 13, 2027." Last confirmed October 29, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/mezigdomide)

Source: Press release filed with the SEC (EX-99), accession 0000014272-26-000018, https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/a2026q2ex991-filing.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/pdufa/mezigdomide#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | mezigdomide |
| Codes | BMS-986348, CC-92480 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [relapsed or refractory multiple myeloma](https://sec-api.dev/indications/relapsed-or-refractory-multiple-myeloma) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Relapsed or Refractory Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05552976 (A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05552976

### September 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Relapsed or Refractory Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05552976 (A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05552976

### May 13, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: relapsed or refractory multiple myeloma.
- First seen 2026-07-30, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0000014272-26-000018): "The FDA accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM), granting a PDUFA date of May 13, 2027." https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/a2026q2ex991-filing.htm
- SEC Form 10-Q (accession 0000014272-26-000024): "(iii) FDA acceptance of our NDA for mezigdomide in RRMM with a PDUFA date of May 13, 2027" https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0000014272-26-000022): "Mezigdomide PDUFA: May 13, 2027 Positive Pivotal Data Readouts Achieved" https://www.sec.gov/Archives/edgar/data/14272/000001427226000022/q32026resultspresentatio.htm
- SEC Form 10-Q (accession 0000014272-26-000024): "The FDA has granted a PDUFA date of May 13, 2027 for this indication." https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm
- SEC Form 10-Q (accession 0000014272-26-000020): "The FDA has granted a PDUFA date of May 13, 2027 for this indication." https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htm

## Same indication

- [Anitocabtagene autoleucel](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) (GILD)

Calendar months: [September 2026](https://sec-api.dev/fda-calendar/2026-09), [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mezigdomide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Mezigdomide PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mezigdomide

```bibtex
@misc{secapidev_pdufa_mezigdomide_20261116,
  title        = {Mezigdomide PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mezigdomide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mezigdomide_20261116","title":"Mezigdomide PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mezigdomide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
